Category Medicines Licensing

MHRA to relaunch the Innovative Licensing and Access Pathway (ILAP) pathway in Q1 2025

Last updated: 9 April 2025 To view updates, click on the ‘+’ sign below: The ILAP first launched in January 2021 to offer an integrated pre-market pathway awarding an Innovation Passport for promising medicines across England, Scotland and Wales. The…

Read MoreMHRA to relaunch the Innovative Licensing and Access Pathway (ILAP) pathway in Q1 2025

New MHRA guidance on the assessment of established medicines in order to help applicants and shorten time frames

New guidance has been published on the MHRA website concerning process changes for the assessment of established medicines that come into effect on 1 March 2024. This post is an attempt to present the guidance information in a manner that…

Read MoreNew MHRA guidance on the assessment of established medicines in order to help applicants and shorten time frames

Swissmedic – changes to various guidance documents for the authorisation of human medicinal products

The table below details changes to five guidance documents (listed in column 1 below) for the authorisation of human medicinal products. Updated guidance document Document (plus form where applicable) What the document concerns Changes to the document Sections of the…

Read MoreSwissmedic – changes to various guidance documents for the authorisation of human medicinal products

MHRA announces new regulatory recognition routes for medicines licensing using approvals from various countries

The UK MHRA has announced today that new regulatory recognition routes for medicines will be established using approvals from the following countries: This means that patients will have access to safe and effective medicines that have been approved by trusted…

Read MoreMHRA announces new regulatory recognition routes for medicines licensing using approvals from various countries

Health Canada updates guidances concerning pre and post-licensing submissions and performance standards for Post-authorization Division 1 Changes (PDCs)

Health Canada has updated guidances concerning pre and post-licensing submissions and performance standards for PDCs for prescription pharmaceutical drugs and those administered or obtained through a health professional. Notice: Revision to the Guidance Document Management of Drug Submissions and Applications…

Read MoreHealth Canada updates guidances concerning pre and post-licensing submissions and performance standards for Post-authorization Division 1 Changes (PDCs)